Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
Alopecia Areata
Medicine & Life Sciences
Alopecia
Medicine & Life Sciences
Scalp
Medicine & Life Sciences
Hair
Medicine & Life Sciences
Hair Follicle
Medicine & Life Sciences
Skin
Medicine & Life Sciences
Finasteride
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2000 2024
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY ANDSAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSIONPERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 ANDPF-067008
6/20/19 → 6/30/24
Project: Research project
Placebos
Safety
A Phase 2B/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata (AA) Subjects with 50% or Greater Scalp Hair Loss
10/9/18 → 10/30/23
Project: Research project
Alopecia Areata
Alopecia
Scalp
Placebos
Safety
A Multicenter, Randomized, Double-Blind, PlaceboControlled, Operationally Seamless, Adaptive Phase 2/3Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very SevereAlopecia Areata
8/6/18 → 8/30/23
Project: Research project
Alopecia Areata
Safety
baricitinib
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability andEfficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects with Alopecia Areata,Alopecia Universalis or Alopecia Totalis
6/15/18 → 6/30/22
Project: Research project
Alopecia Areata
Alopecia
Multicenter Studies
Suspensions
Placebos
Research Output 1982 2019
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity
Pease, D. F., Peterson, B. A., Gilles, S., Hordinsky, M. K., Bohjanen, K. A. & Skubitz, K. M., Jul 1 2019, In : Cancer chemotherapy and pharmacology. 84, 1, p. 217-221 5 p.Research output: Contribution to journal › Article
Toxicity
Squamous Cell Carcinoma
Skin
Foot
Cutaneous T-Cell Lymphoma
1
Citation
(Scopus)
Evidence for neurogenic inflammation in lichen planopilaris and frontal fibrosing alopecia pathogenic mechanism
Doche, I., Wilcox, G. L., Ericson, M. E., Valente, N. S., Romiti, R., McAdams, B. D. & Hordinsky, M. K., Jan 1 2019, In : Experimental Dermatology.Research output: Contribution to journal › Article
Neurogenic Inflammation
Lichens
Alopecia
Scalp
Calcitonin Gene-Related Peptide
Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin
Goyal, A., Hordinsky, M. K. & Lazaryan, A., Mar 1 2019, In : Dermatologic Therapy. 32, 2, e12835.Research output: Contribution to journal › Article
Mycosis Fungoides
Anaplastic Large-Cell Lymphoma
Stem Cells
Therapeutics
Transplants
Thirty years (and more) of hair research societies
Westgate, G. E., Bergfeld, W. F., Ceh, V., Hordinsky, M., Sinclair, R., Piraccini, B. M., Kang, H. & Ohyama, M., Aug 2019, In : Journal of the American Academy of Dermatology. 81, 2, p. 652-653 2 p.Research output: Contribution to journal › Editorial
Research
1
Citation
(Scopus)
Alopecia Areata: The Clinical Situation
Hordinsky, M. K., Jan 1 2018, In : Journal of Investigative Dermatology Symposium Proceedings. 19, 1, p. S9-S11Research output: Contribution to journal › Comment/debate
Alopecia Areata
Hair Diseases
Therapeutics
Alopecia
United States Food and Drug Administration